Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553-63.
McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69:230-8.
Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81:1207- 14.
Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78:381-5.
Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10:759-72.
Hernandez-Echebarria L, Saiz A, Ares A, Tejada J, Garcia-Tufion L , Nieves C, Graus F. Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti- GAD antibodies. Neurology. 2006;66:450-1.
Piccolo G, Tavazzi E, Cavallaro T, Romani A, Scelsi R, Martino G. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J Neurol Sci. 2010;290:148-9.
Mata S, Muscas GC, Cincotta M , Bartolozzi ML, Ambrosini S, Sorbi S. GAD antibodies associated neurological disorders: incidence and phenotype distribution among neurological inflammatory diseases. J Neuroimmunol. 2010;227:175-7.
Rakocevic G, Floeter MK. Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. Muscle Nerve. 2012;45:623-34.
Warren JD, Scott G, Blumbergs PC, Thompson PD. Pathological evidence of encephalomyelitis in the stiff man syndrome with anti-GAD antibodies. J Clin Neurosci. 2002;9:328-9.
Olson JA, Olson DM, Sandborg C, Alexander S, Buckingham B. Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics. 2002;109:E50.
Goldberg EM, Taub KS, Kessler SK, Abend NS. Anti- NMDA receptor encephalitis presenting with focal non- convulsive status epilepticus in a child. Neuropediatrics. 2011;42:188-90.
Espay AJ, Kumar V, Sarpel G. Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus. J Neurol Sci. 2006;246:149-52.
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67:470-8.
DENEYSEL TIP ARAŞTIRMA ENSTİTÜSÜ DERGİSİDİR
Year 2012,
Volume: 2 Issue: 3, 23 - 27, 21.05.2012
Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553-63.
McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69:230-8.
Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, Lennon VA. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81:1207- 14.
Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007;78:381-5.
Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10:759-72.
Hernandez-Echebarria L, Saiz A, Ares A, Tejada J, Garcia-Tufion L , Nieves C, Graus F. Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti- GAD antibodies. Neurology. 2006;66:450-1.
Piccolo G, Tavazzi E, Cavallaro T, Romani A, Scelsi R, Martino G. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J Neurol Sci. 2010;290:148-9.
Mata S, Muscas GC, Cincotta M , Bartolozzi ML, Ambrosini S, Sorbi S. GAD antibodies associated neurological disorders: incidence and phenotype distribution among neurological inflammatory diseases. J Neuroimmunol. 2010;227:175-7.
Rakocevic G, Floeter MK. Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. Muscle Nerve. 2012;45:623-34.
Warren JD, Scott G, Blumbergs PC, Thompson PD. Pathological evidence of encephalomyelitis in the stiff man syndrome with anti-GAD antibodies. J Clin Neurosci. 2002;9:328-9.
Olson JA, Olson DM, Sandborg C, Alexander S, Buckingham B. Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics. 2002;109:E50.
Goldberg EM, Taub KS, Kessler SK, Abend NS. Anti- NMDA receptor encephalitis presenting with focal non- convulsive status epilepticus in a child. Neuropediatrics. 2011;42:188-90.
Espay AJ, Kumar V, Sarpel G. Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus. J Neurol Sci. 2006;246:149-52.
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67:470-8.
Ulusoy, C., Turan, S., & Tüzün, E. (2012). GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU. Deneysel Tıp Araştırma Enstitüsü Dergisi, 2(3), 23-27.
AMA
Ulusoy C, Turan S, Tüzün E. GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU. Deneysel Tıp Araştırma Enstitüsü Dergisi. July 2012;2(3):23-27.
Chicago
Ulusoy, Canan, Selin Turan, and Erdem Tüzün. “GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU”. Deneysel Tıp Araştırma Enstitüsü Dergisi 2, no. 3 (July 2012): 23-27.
EndNote
Ulusoy C, Turan S, Tüzün E (July 1, 2012) GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU. Deneysel Tıp Araştırma Enstitüsü Dergisi 2 3 23–27.
IEEE
C. Ulusoy, S. Turan, and E. Tüzün, “GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU”, Deneysel Tıp Araştırma Enstitüsü Dergisi, vol. 2, no. 3, pp. 23–27, 2012.
ISNAD
Ulusoy, Canan et al. “GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU”. Deneysel Tıp Araştırma Enstitüsü Dergisi 2/3 (July 2012), 23-27.
JAMA
Ulusoy C, Turan S, Tüzün E. GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU. Deneysel Tıp Araştırma Enstitüsü Dergisi. 2012;2:23–27.
MLA
Ulusoy, Canan et al. “GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU”. Deneysel Tıp Araştırma Enstitüsü Dergisi, vol. 2, no. 3, 2012, pp. 23-27.
Vancouver
Ulusoy C, Turan S, Tüzün E. GLUTAMİK ASİT DEKARBOKSİLAZ ANTİKORU’NUN OTOİMMUN ENSEFALİTTEKİ SIKLIĞI VE KLİNİK SPEKTRUMU. Deneysel Tıp Araştırma Enstitüsü Dergisi. 2012;2(3):23-7.